Read + Share
Miyake M. Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for
Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder
Cancer: A Copula-Based Secondary Analysis. Int J Urol 2026;33:e70699.
PMID: 42978047
|
 |
|
